$2.66
▼ -0.8% Today
as of Oct 23, 16:46 ET
Last 30 days
Recent Press Releases & News
Oppenheimer Adjusts Price Target on BridgeBio Oncology Therapeutics to $16 From $22, Maintains Outperform Rating
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
BBOT earnings at a glance
Over its last 1 reports the stock rose the next day 1 time and fell 0, moving ±3.0% on average; after the most recent report on May 12, 2026 it moved +3.0%. BBOT beat the consensus EPS estimate in 0 of its last 2 reported quarters. The share price of $2.66 sits near its 52-week low.
Overview
52-week range
$2.60
$15
0% of range
Avg surprise (last 2)
-77.6%
Avg reaction (last 1)
+3.0%
100% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-705.20 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.53 | $-0.51 | -3.9% | — | +3.0% | earnings |
| Wed Nov 12, 2025 | Sep/2025 | $-1.03 | $-0.41 | -151.2% | — | — | earnings |
| Mon Jun 30, 2025 | Jun 2025 | $-566.46 | — | — | — | — | financials |
| Mon Mar 31, 2025 | Mar 2025 | $-54.23 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-1562.18 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-60M | $-46M | — | $-49M | $-30M | $-23M | — | $-20M |
| Net income | $-56M | $-42M | — | $-45M | $-28M | $-22M | — | $-17M |
| EPS (diluted) | $-705.20 | $-526.11 | — | $-1.03 | $-566.46 | $-54.23 | — | $-1562.18 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $54M | $53M | $374M | $409M | $664,231 | $963,135 | $31M | $2M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $242M | $267M | $432M | $476M | $876,779 | $1M | $159M | $2M |
| Total assets | $377M | $418M | $448M | $485M | $197M | $196M | $164M | $192M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $54M | $45M | $37M | $38M | $8M | $7M | $20M | $6M |
| Total equity | $323M | $372M | $411M | $447M | $-228M | $-200M | $-179M | $-159M |
Implied volatility — last 90 days
No IV snapshots yet for BBOT.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.
Sector peers
BBOT earnings FAQ
How does BBOT stock usually react to earnings?
Across the last 1 reports the average next-day move was ±3.0%, up 1 times and down 0 times.